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Abstract
Introduction: Ketamine has a fast, but short-term antidepressant effect. To support the therapeutic effect, repeated 
administrations of the drug are needed, which causes cognitive disorders. The drugs with cerebroprotective action can 
potentially intensify the main and weaken the side effects of drugs.
Materials and methods: The impact of ketamine (5 and 20 μM), piracetam (100 μM), and their combinations on the 
synaptic transmission was studied on hippocampal slices in the CA1 area of rat hippocampus by means of electrophys-
iological methods. In behavioral experiments were aimed at studying an impact of the used drugs on the predictors 
which mark depressant behavior of rats: the duration of immobilization in a forced swimming test and preference for 
the consumption of sucrose solution (comparably with water). The behavioral experiments were performed on intact 
rats and rats with behavioral depression induced by chronic swimming stress.
Results and discussion: Ketamine (5 and 20 μM) potentiates synaptic transmission in the radial layer of the CA1 hip-
pocampal area. At a smaller concentration, ketamine potentiates synaptic transmission only due to the postsynaptic ac-
tion, and at a greater concentration – with help of post- and presynaptic action. Piracetam (100 µM), like ketamine at a 
concentration of 5 μM stimulated synaptic transmission, but to a lesser degree. Ketamine at a concentration 5 μM under 
combined effect with piracetam induced the same effect as that at a concentration of 20 μM without piracetam, only due 
to a postsynaptic action. Ketamine at doses of 5 and 20 mg/kg one hour after a single systemic administration resulted 
in the reduced immobilization duration, but not predictors of preference for consuming a sweet solution; piracetam at a 
dose of 100 mg/kg under these conditions had no impact on the parameters of the rats’ behavior. The studied behavior 
parameters in cases of behavioral depression also changed after a single administration of ketamine at the doses of 5 and 
20 mg/kg. Piracetam significantly stimulated an antidepressant action of ketamine under these circumstances.
Conclusion: Piracetam potentiates a ketamine-induced enhancement of the synaptic transmission at the radial layer 
of the CA1 hippocampal area when investigating at the brain slices. Piracetam stimulates an antidepressant action of 
a single dose of ketamine in cases of behavioral depression, though it has no antidepressant effect when administered 
at a single dose.
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Introduction
Major depressive disorder (MDD), prevailing in 7–12% 
of men and 20–25% of women, is a leading cause of disa-
bility and a serious public health problem. The current 
estimates by the WHO caution that MDD will become 
the second leading cause of disability after 2020. In ad-
dition to the increasing prevalence and the behavioral se-
quelae with it, MDD is an enormous economic burden 
on society. The existing treatments of MDD usually last 
from weeks to months to achieve their antidepressant ef-
fects, and many patients do not experience any sufficient 
improvement even after months of treatment. There is a 
danger of patients committing suicides during treatment. 
The fact is that twice as many people die from commit-
ting suicide each year than by homicide, and every fourth 
suicide victim had been treated by antidepressants until 
death (Greenberg et al. 2015, Karch 2012).
Early 2000 showed that a single sub-anesthetic dose 
(0.5 mg/kg) of ketamine, a non-selective non-competitive 
antagonist of ionotropic N-methyl-D-aspartate (NMDA) 
glutamatergic receptors, produced a rapid and long-last-
ing antidepressant effects in patients suffering from MDD 
(Berman et al. 2000). But together with a pronounced 
antidepressant effect, ketamine also has a psychosis-pro-
ducing properties, thus there is a threat of development 
of drug abuse (Browne and Lucki 2013). Adverse side 
effects of ketamine require correction, but the ways of do-
ing so are poorly apprehended.
In pre-clinical trial, it was discovered that drugs with 
brain protective activity, e.g. piracetam (nootropil), rein-
force an impact of tricyclic antidepressant imipramine on 
manifestations of behavioral depression in rats caused by 
a swimming stress (Zayka et al. 2018). Against the back-
ground of piracetam, a partial dose of imipramine pro-
duces the same effect as a full dose of an antidepressant. 
This fact is of interest because, if there is a chance of ad-
verse side effects of using some drug when increasing its 
dose, by potentiating the effect of this drug it is possible to 
achieve the main effect at lesser drug doses, thus decrease 
the chance of adverse side effects.
The paper presents the results of studying the influence 
of nootropic drug piracetam on changes of glutamater-
gic synaptic transmission in the CA1 hippocampal area 
caused by sub-anesthetic doses of ketamine. At the same 
time, the paper looks at the changes of influence of keta-
mine on a duration of immobility in the forced swimming 
test and the preference for consuming sweet solution in 
cases of behavioral depression induced by chronic swim-
ming stress at the background of piracetam action.
Materials and methods
The research was performed on white inbred rats. The 
impact of ketamine and piracetam on glutamatergic trans-
mission in the synapses formed by axons of pyramidal 
neurons of the CA3 area (Schaffer’s collaterals) and by 
dendrites of pyramidal neurons of the CA1 area was stu-
died on the slices of the hippocampus, using a conventi-
onal electrophysiological method. The electrophysiologi-
cal studies were performed on the slices of the rat dorsal 
hippocampus. The details of the method were given in 
(Abramets et al. 2011). The dorsal hippocampus was iso-
lated from the posterior pole of the brain. The 400 μm 
thick slices were prepared using a Vibratome. The field 
(f) excitatory postsynaptic potentials (EPSP) of pyrami-
dal neurons of the CA1 region, which had been caused 
by electrical stimulation of Schaffer’s collaterals, were 
recorded extracellularly in the hippocampus slices, using 
glass microelectrodes filled with 2 M of NaCl solution 
with tip resistance of 2–5 megohms. The stimulation of 
synaptic inputs was carried out by a bipolar nickel-chro-
mium electrode by rectangular current pulses of 0.1 ms 
duration. The N-methyl-D-aspartate (NMDA) compo-
nent of the fEPSP of pyramidal hippocampal neurons was 
isolated pharmacologically. To do this, the brain slices 
were superfused with Krebs solution with a concentra-
tion of Mg2+ reduced to 0.2 mM (in favour 1 mM) and 
the addition of 10 μM of an α-amino-3-hydroxy-5-me-
thyl-4-isoxazolepropionic acid (AMPA) receptor blocker 
– 6,7-dinitroquinoxalin-2,3-dione (DNQX), 50 μM of a 
non-competitive GABAA receptors blocker picrotoxin 
and 1 μM of a co-agonist of NMDA receptors, glycine. 
Paired pulse ratio (PPR) was determined as a ratio of the 
second/first amplitudes of fEPSP caused at an interpulse 
interval of 50 ms.
The level of depressiveness in rats was assessed by re-
cording the parameters of the forced swimming test (FST) 
(Porsolt et al. 1978). The rats were placed in a plexiglass 
cylinder of 46 cm in diameter and 45 cm in height, filled 
with water (temperature 23–25 °C) to a level of 30 cm 
from the bottom. On the first day, the duration of the 
swimming was 15 minutes (pre-test); 24 hours later, the 
rats were placed in water for 6 minutes, and, using vide-
orecording, the basic parameters of their behavior were 
recorded and stored in a separate file. The immobilization 
behavior was characterized by positioning the rats verti-
cally, motionless, with their forelegs pressed to the chest, 
hind legs extended, and the head above the water. The 
longer immobilization lasted, the higher level of depres-
sion the animals had.
The test of sucrose preference characterizing a hedon-
ic behavior of rats was carried out by the method from 
(Benelli et al. 1999). For this, on the first day, the rats 
were placed in individual cages with two drinking bowls 
filled with 1% sucrose solution. The next day, there was 
water in one drinking bowl, and the solution of sucrose 
– in the other. For 23 hours on the third day, the animals 
were deprived of food and water, and then 2 pre-weighed 
drinking bowls filled with water and a solution of sucrose 
were returned to the cages for 60 minutes. One hour later, 
the drinking bowls were weighed. In the next 2 hours of 
the fourth day, the animals received food and water, after 
which they were deprived of food and water for 21 hours. 
Then again, the drinking bowls were returned for 1 hour, 
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and the percentage of preference for the consumption of 
sucrose solution (P) was determined by the formula (1):
= The  weight  of  consumed  sucrose  solution
 The  weight  of  consumed  liquid
  100           
 
 
 
 
 
 
 (1)
First, an impact of intraperitoneally (i/p) administrated 
ketamine (5 and 20 mg/kg) and piracetam (100 mg/kg) 
on rats’ immobilization duration in FST was studied, as 
well as the percentage of preference for consumption of 
sucrose solution (PCSS) in the intact rats. Then, a depres-
sion syndrome was simulated according to the method 
from (Sun et al. 2011). For that, after determination of the 
initial behavioral indicators on the first day, for the next 
five days the rats were subjected to a swimming stress by 
placing the animals in water for 10 min. On the sixth day, 
after terminating the stress procedure, the rats were divid-
ed into 6 groups. The rats of Group 1 were administrated 
piracetam (100 mg/kg) i/p and 30 min later – ketamine (5 
mg/kg). The rats of Group 2 also received piracetam and 
ketamine (20 mg/kg). The rats of Groups 3 and 4 were 
administrated a some volume vehicle as it with piracetam 
i/p and 30 min later – ketamine at doses of 5 and 20 mg/
kg, respectively. The rats of Group 5 received piracetam 
(100 mg/kg) and 30 min later – a dosing vehicle. The rats 
of Group 6 were administrated the vehicle twice, at 30 
min interval. One hour after the last injection, the immo-
bilization duration in FST was determined in the rats of 
the first halves of each group, and in the second halves – 
percentage of PCSS. Each group had 6–8 rats .
The research results were analyzed using the conven-
tional methods of variation statistics and licensed Medstat 
software. For each series, the mean and standard error of 
the mean were determined. The significance of the differ-
ences in the compared values was assessed using a paired 
Student t-test.
Results and discussion
The study looked at the impact of (R,S)-ketamine at con-
centration of 5 and 20 μM, which approximately cor-
responded to the doses of 5 and 20 mg/kg systemically 
administrated to rats, on glutmatergic excitatory synaptic 
transmission in the CA1 area of hippocampus. Amplitudes 
of fEPSPs of pyramidal neurons of the CA1 area signifi-
cantly increased to 122.1±4.9 % (p<0.05) against control 
under the influence of Krebs solution with 5 μM of ke-
tamine on the slices for 60 min. With ketamine at a dose 
of 20 μM influencing the slices, the amplitude of fEPSPs 
increased (p<0.01) to a greater extent to 166.8±6.6 % (Fig. 
1). The complex postsynaptic EPSP of pyramidal neurons 
have two components, due to the action of glutamate 
on postsynaptic AMPA and NMDA glutamate receptors 
(Hestrin et al. 1990). Under the action of ketamine (5 μM) 
on slices, the amplitude of an NMDA component of fEPSP 
hardly changed; but it significantly (p<0.05) increased to 
119.4 ± 4.2 % under the influence of ketamine at a dose 
of 20 μM (Fig. 1). To identify the localization of ketamine 
action (pre- or postsynaptic) on the pyramidal neuron sy-
napses, the ranges of correlation between the amplitudes 
of the second responses to the amplitudes of the first res-
ponses were measured at 50 ms interpulse interval (PPR). 
Thus, with ketamine (5 μM) impact on slices, PPR did not 
change – 1.64±0.09 against 1.75 ± 0.09 in control; with an 
increased concentration of ketamine to 20 μM, PPR signi-
ficantly (p<0.05) decreased to 1.37 ± 0.07 (Fig. 1).
When affecting hippocampal slices, ketamine, though 
it noncompetitively blocks all types of NMDA gluta-
mate receptors, caused increased amplitudes in fEPSP 
of pyramidal neurons (Fig. 1). This effect may be due 
to increasing of efficacy of postsynaptic AMPA gluta-
mate receptors or enhancement of presynaptic release 
of a mediator from the Schaffer’s collaterals. Apparent-
ly, ketamine (5 μM) operates postsynaptically, which 
is proved by increased amplitudes of complex fEPSPs 
without shifts in amplitudes of their NMDA components 
and PPR (Fig. 1). On the other hand, ketamine (20 μM) 
enhances synaptic transmission predominantly in a pre-
synaptic way. Indeed, along with increased amplitudes of 
complex fEPSPs, there was an increased in amplitudes of 
their NMDA components and a decrease in PPR (Fig. 1), 
meaning enhancement of presynaptic release of the medi-
ator (Foster and McNaughton 1991).
Ketamine-induced enhancement of glutamatergic syn-
aptic transmission in hippocampus was also observed 
by other researchers (Autry et al. 2011, Nosyreva et al. 
Figure 1. Impact of ketamine on parameters of synaptic trans-
mission in pyramidal neurons of CA1 hippocampal area. Note: 
A – oscillograms of complex fEPSPs of pyramidal neurons, ob-
tained in a separate experiment; 1 – control, 2 –one hour later with 
5 μM of ketamine, 3 – one hour later with 20 μM of ketamine; 
B – three overlapping oscillograms; C – dependence of chang-
es in amplitudes of complex fEPSPs on acting concentrations of 
ketamine; 1 – control, 2 and 3 – ketamine action at concentrations 
of 5 and 20 μM, respectively; D – changes of PPR of fEPSPs with 
ketamine impact on slices; 1–3 – as in C; E – ketamine impact 
on amplitudes of NMDA components of fEPSPs of pyramidal 
neurons; 1 – control, 2 and 3 – with ketamine at concentrations of 
5 and 20 μM, respectively. Calibrations – 0.2 mV; 5 ms. * and ** 
– differences are significant at p<0.05 and p<0.01, respectively.
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2013). But the nature of this phenomenon is still not clear. 
It may be due to enhanced phosphorylation of Ser845 in 
the structure of GluA1 subunit [site of protein kinase A 
(PKA)] and intensification of the subunit transport to the 
surface of a neuron. Ketamine-induced enhancement of 
synaptic transmission was prevented by PKA inhibitor 
H89; a blocker of tyrosine kinase receptors K225a and 
an inhibitor of protein translation anisomycine inhibited 
GluA1 subunit transport to the surface of a neuron and 
in postsynapsis (Zhang et al. 2017). These changes can 
be due to blockade by ketamine of postsynaptic NMDA 
glutamate receptors. It was determined that ketamine used 
at certain range of doses blocks miniature EPSPs at phys-
iological concentrations of Mg2+, whereas spotaneous 
Ca2+-independent release of glutamate from Schaffer’s 
collaterals regulates the number of postsynaptic AMPA 
glutamate receptors and synaptic plasticity (Autry et al. 
2011). An inhibition of spontaneous release of glutamate 
or miniature EPSPs in synapses causes an increased ac-
tivity of elongation factor of eEF2 kinase and enhances 
the local dendritic translation of proteins, primarily, neu-
rotrophin BDNF and GluA1 subunit of AMPA receptors.
Enhancement of glutamate presynaptic release, caused 
by 20 µM ketamine, is associated with blockade of more 
ketamine-sensitive NMDA glutamate receptors, contain-
ing GluN2C and GluN2D subunits, in Schaffer’s collater-
als (Zhang et al. 2017). Along with this, ketamine blocks 
an HCN1 subunit of cationic channels activated by hyper-
polarization and cyclic nucleotide-gated (HCN). In turn, 
the blocking of HCN channels increases the activity of 
voltage gated Cav2.3 channels and enhances presynaptic 
release of glutamate (Noam et al. 2010, Huang et al. 2011). 
S-ketamine is twice as powerful as RS-ketamine when 
blocking HCN1 cationic channels and EC50 of RS-ket-
amine when blocking NMDA glutamate receptors ~ four 
times as weaker as its EC50 by its ability to inhibit HCN 
cationic channels (Chen et al. 2009). Therefore, to inhibit 
HCN1 channels and enhance presynaptic release of gluta-
mate, higher doses of ketamine are needed. Ketamine at 
doses of 3–10 mg/kg, which approximately correspond to 
brain concentration of 3–10 μМ, produces a pronounced 
antidepressant effect (Autry et al. 2011) and enhances the 
synaptic transmission in hippocampus due to postsynap-
tic mechanisms (Fig. 1). At greater doses (20–30 mg/kg), 
ketamine also produces an antidepressant effect and en-
hances presynaptic release of glutamate in the hippocam-
pal synapses (Zhang et al. 2017; Fig. 1). It remains unclear 
whether presynaptic mechanism of ketamine has anything 
to do only with an antidepressant, or with both antidepres-
sant, and psychodelic effects of the drug.
The nootropic drug piracetam influenced the synaptic 
transmission at synapses formed by Schaffer’s collaterals 
and dendrites of pyramidal neurons of the CA1 area of 
hippocampus. When piracetam (100 μM) affects slices, 
the amplitudes of complex fEPSPs of pyramidal neurons 
significantly (p<0.05) increased to 122.4±5.1 % in rela-
tion to control (Fig. 2). The increase in amplitudes of com-
plex fEPSPs was not followed by changes in amplitudes 
of their NMDA components (Fig. 2). Piracetam did not 
affect PPR: 1.64±0.11 against 1.76±0.12 in control (Fig. 
2). These facts mean that piracetam stimulates the synap-
tic transmission in hippocampus through a postsynaptic 
mechanism. In fact, piracetam exhibits the properties of 
an AMPAkine, i.e. increases the amplitude of synaptic re-
sponses by potentiating the AMPA component of fEPSPs. 
The potentiating action of piracetam on fEPSPs was con-
ditioned by reduced desensitization of AMPA glutamate 
receptors caused by glutamate, which is characteristic of 
AMPAkines (Ahmed and Oswald 2010).
Piracetam enhanced an impact of ketamine on synap-
tic transmission in the CA1 area of hippocampus. In fact, 
preliminary action of 100 μM piracetam for 30 min on 
the slices caused an increase in amplitudes of complex 
fEPSPs of pyramidal neurons to 121.3±4.7 % in relation 
to control. The influence of 5 μM ketamine on slices in 
the presence of piracetam 60 min later induced a further 
increase in amplitudes of complex fEPSPs to 167.6±5.8 
% in relation to control (Fig. 3). But ketamine (5 μM) had 
no impact on PPR – 1.68±0.13 in control and 1.71±0.11 
after the influence of ketamine (Fig. 3). It means that a 
significant increase in amplitudes of complex fEPSPs of 
pyramidal neurons of the CA1 hippocampal area induced 
by a joint action of ketamine and piracetam was condi-
tioned by the postsynaptic mechanism. An increased reac-
tivity of postsynaptic AMPA glutamate receptors, under-
lying this mechanism, may be a consequence of enhanced 
phosphorylation of Ser845 in GluA1 receptor subunit and 
reduced desensitization of AMPA receptors (Zhang et 
al. 2017, Ahmed and Oswald 2010). It is important that 
a combined action of piracetam and 5 μM ketamine on 
Figure 2. Piracetam enhances synaptic transmission in pyramidal 
neurons of the CA1 hippocampal area. Note: A top – overlapping 
oscillograms of complex fEPSPs of pyramidal neurons before 
(1), 30 min after piracetam’s (100 μM) action on slices (2); A 
bottom – overlapping oscillograms of NMDA components of 
fEPSPs of pyramidal neurons before (1) and after (2) piracetam’s 
action. The oscillograms were obtained in a separate experiment. 
B and C –impact of 100 μM of piracetam on amplitudes of com-
plex fEPSPs of pyramidal neurons and PPR, respectively. Cali-
brations – 0.2 mV; 5 ms. * – differences are significant at p<0.05.
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slices results in the same effect as only 20 μM ketamine is 
applied on slices (Fig. 1, 3). However, in the latter case, an 
increase in amplitudes of complex fEPSPs was caused by 
both post- and presynaptic mechanisms. In the presence 
of piracetam, when ketamine at concentration of 20 μM 
was applied on slices, there was an increase in amplitudes 
of complex fEPSPs to 178.8±5.3 % against 159.7±4.9 % 
without piracetam in relation to control (Figs 1, 3). It is of 
interest that under the joint influence of piracetam and 20 
μM ketamine on slices, an unreliable trend was found to-
wards the weakening of a presynaptic action of ketamine: 
PPR under the influence of ketamine only was 1.37±0.07, 
whereas under the influence of both drugs it was 1.49±0.08 
(Figs 1, 3). Consequently, piracetam enforces the action of 
ketamine on synaptic transmission in hippocampus pre-
dominantly through postsynaptic mechanisms.
Further, the study examined an impact of ketamine and 
piracetam on behavioral parameters of the intact rats re-
lating to behavioral depression. One hour after i/p admin-
istration of 5 mg/kg ketamine, the time of immobilization 
of the rats in forced swimming test (FST) significantly re-
duced; after administration of a greater (20 mg/kg) dose, 
the time of immobilization reduced to a greater extent (Ta-
ble 1). The differences of the effects of the two doses of 
ketamine, however, are unrealiable (P=0,141), therefore 
the assumption about dose-dependent ketamine effects is 
wrong. At both doses used, ketamine has no effect (Ta-
ble 1) on the percentage of preference for consumption of 
sucrose solution (PCSS). Other researchers (Li et al. 2011) 
also observed no ketamine impact on this predictor in the 
intact animals. Piracetam at a dose of 100 mg/kg had no 
influence on either behavioral parameters (Table 1).
One day after the termination of the swimming stress 
impact, behavioral depression was observed, which was 
marked by an increased immobilization duration in FST 
and by anhedonia – a decreased PCSS (Table 2). One 
hour after a single administration of ketamine at both 
doses to rats, under these circumstances the manifesta-
tions of behavioral depression were observed weakening: 
a decrease in immobilization duration and an increase 
in PCSS (Table 2). A single administration of piracetam 
had no influence on animal’s behavior (Table 2). The ef-
fects of ketamine administrated on the background of the 
action of piracetam significantly increased; the effect of 
ketamine on behavior at a dose of 5 mg/kg under these 
circumstances exceeded its effects at a dose of 20 mg/kg 
without piracetam (Table 2). Therefore, piracetam inten-
sifies the impact of single-administered ketamine on the 
animals’ behavior in stress-induced behavioral depres-
sion. It still remains unclear why both tested drugs stim-
ulate synaptic transmission in hippocampus through the 
postsynaptic action, but single-administered ketamine ex-
hibits an antidepressant effect, whereas piracetam has no 
Table 1. An impact of tested drugs on behavioral responses in 
control rats.
Administered drugs Time of 
immobilization (s)
% preference for 
consumption of sucrose 
solution
Control (vehicle) 59.4±3.4 79.4±2.4
Ketamine 5 mg/kg 
after 60 min
46.4±3.2* 72.1±2.5
Ketamine 20 mg/kg 
after 60 min
38.7±3.6* 83.6±3.1
Piracetam 100 mg/kg 
after 60 min
62.2±3.6 75.8±4.24
Note: * – differences are significant at p<0.05.
Figure 3. Piracetam potentiates an impact of ketamine on syn-
aptic transmission in pyramidal neurons of the CA1hippocam-
pal area. Note: A left – overlapping oscillograms of complex 
fEPSPs of pyramidal neurons before (1) and 30 min after ap-
plying 100 μM of piracetam onto slices (2) and 60 min after 
applying ketamine (5 μM) in the presence of piracetam (3). A at 
center – changes in amplitudes of complex fEPSPs. A right – 
changes in PPRs in control (1), under the influence of piracetam 
(2) and of ketamine and piracetam (3). B – the same under the 
influence of piracetam (100 μM) and ketamine (20 μM) on slic-
es. Calibrations – 0.2 mV; 5 ms. * and ** – differences are sig-
nificant at p<0.05 and p<0.01, respectively.
Table 2. Impact of tested drugs on behavioral responses of rats 
in behavioral depression caused by swimming stress.
Administered drugs Time of 
immobilization (s)
% preference for 
consumption of 
sucrose solution
Control (vehicle) 59.4±3.4 79.4±2.4
1th day after termination 
of swimming stress 
(vehicle)
114.0±5.1* 54.0±1.8*
Ketamine 5 mg/kg after 
60 min 79.8±3.9
# 66.1±2.1#
Ketamine 20 mg/kg after 
60 min 68.4±3.7
# 71.2±2.3#
Piracetam 100 mg/kg 
after 30 min
99.4±5.4 59.6±2.4
Piracetam 100 mg/kg 
after 30 min + ketamine 
5 mg/kg after 60 min
54.7±3.1# ^ 85.5±3.2# ^
Piracetam 100 mg/kg 
after 30 min + ketamine 
20 mg/kg after 60 min
47.4±4.1# ^ 88.3±4.2# ^
Note: * – differences from control, # – from indicators after stress im-
pact, ^ – from indicators against the action of ketamine only at doses of 
5 and 20 mg/kg are significant at p<0.05.
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such effect. So piracetam increases the functional activity 
of the existing postsynaptic AMPA glutamate receptors, 
whereas ketamine, by activating a signal pathway mTOR, 
intensifies translation and expression of presynaptic pro-
teins Arc and synapsin I, postsynaptic protein PSD95 and 
GluA1 subunit of AMPA receptors, which are involved in 
formation, maturation and functioning of new spine syn-
apses (Li et al. 2010). However, only after chronic admin-
istration, piracetam exhibits an antidepressant-like effect 
(Zayka et al. 2018).
The main advantage of ketamine is it fast antidepres-
sant effect, but it lasts a week at most, therefore requiring 
the repeated administration of the drug. This is accom-
panied by adverse side effects – cognitive disturbances, 
disorders of memory, psychotic symptoms, increasing of 
oxidative stress in brain and developing drug addiction 
(Zuo et al. 2007, Krystal et al. 2005). To reduce adverse 
side effects and to enhance an antidepressant effect of 
ketamine, it is recommended that ketamine be combined 
with a mood stabilizer lithium (Chiu et al. 2014). Lithi-
um is known to directly inhibit both isoforms of kinase-3 
glycogensynthase (GSK-3) and to enhance expression of 
neurotrophin BDNF, which provides for a pronounced 
cerebroprotective effect of the drug (Liu et al. 2013). Pi-
racetam also has a pronounced cerebroprotective effect 
(Vostrikov 2017) and enhances neuronal and behavioral 
effects of ketamine. In fact in the presence of piracetam, 
ketamine at a concentration of 5 μM causes the same neu-
ronal effect as at its concentration of 20 μM without pi-
racetam; however, ketamine (5 μM) does not stimulate 
presynaptic release of glutamate (Fig. 3). On the other 
hand, ketamine in the systemic administration at a dose of 
5 mg/kg, which approximately сorresponds to the concen-
tration of 5 μM affecting the slices, causes an antidepres-
sant effect (Table 2). Therefore, the postsynaptic effect of 
low concentrations of ketamine on the brain limbic struc-
tures is sufficient for developing of antidepressant effect. 
An addition of a presynaptic component – influence of 
ketamine at greater doses/concentrations – stimulates the 
antidepressant effect of the drugs, but it can be a source of 
psychotic side effect. One of the advantages of piracetam 
as a potentiator of ketamine action is better patients’ toler-
ance towards it, when compared with lithium.
Conclusion
Piracetam potentiates enhancement of the ketamine-indu-
ced synaptic transmission in the radial layer of the CA1 
hippocampal area in studies of the brain slices. When 
administered systemically, piracetam enhances an antide-
pressant effect of single-administered ketamine in behavi-
oral depression, though piracetam has no antidepressant 
effect on its own in single administration.
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